126 related articles for article (PubMed ID: 17303971)
1. Better patient persistence with once-daily bupropion compared with twice-daily bupropion.
Stang P; Young S; Hogue S
Am J Ther; 2007; 14(1):20-4. PubMed ID: 17303971
[TBL] [Abstract][Full Text] [Related]
2. Persistence with once-daily versus twice-daily bupropion for the treatment of depression in a large managed-care population.
Stang P; Suppapanaya N; Hogue SL; Park D; Rigney U
Am J Ther; 2007; 14(3):241-6. PubMed ID: 17515697
[TBL] [Abstract][Full Text] [Related]
3. Once-daily bupropion associated with improved patient adherence compared with twice-daily bupropion in treatment of depression.
McLaughlin T; Hogue SL; Stang PE
Am J Ther; 2007; 14(2):221-5. PubMed ID: 17414593
[TBL] [Abstract][Full Text] [Related]
4. An assessment of patient preference and adherence to treatment with Wellbutrin SR: a web-based survey.
Granger AL; Fehnel SE; Hogue SL; Bennett L; Edin HM
J Affect Disord; 2006 Feb; 90(2-3):217-21. PubMed ID: 16360216
[TBL] [Abstract][Full Text] [Related]
5. Bupropion sustained release: side effect profile.
Settle EC
J Clin Psychiatry; 1998; 59 Suppl 4():32-6. PubMed ID: 9554319
[TBL] [Abstract][Full Text] [Related]
6. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
Jefferson JW; Pradko JF; Muir KT
Clin Ther; 2005 Nov; 27(11):1685-95. PubMed ID: 16368442
[TBL] [Abstract][Full Text] [Related]
7. Bupropion extended-release for depressive disorders.
Jefferson JW
Expert Rev Neurother; 2008 May; 8(5):715-22. PubMed ID: 18457528
[TBL] [Abstract][Full Text] [Related]
8. Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL.
Modell JG; Rosenthal NE; Harriett AE; Krishen A; Asgharian A; Foster VJ; Metz A; Rockett CB; Wightman DS
Biol Psychiatry; 2005 Oct; 58(8):658-67. PubMed ID: 16271314
[TBL] [Abstract][Full Text] [Related]
9. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.
Evins AE; Cather C; Culhane MA; Birnbaum A; Horowitz J; Hsieh E; Freudenreich O; Henderson DC; Schoenfeld DA; Rigotti NA; Goff DC
J Clin Psychopharmacol; 2007 Aug; 27(4):380-6. PubMed ID: 17632223
[TBL] [Abstract][Full Text] [Related]
10. Bupropion-SR in treatment of social phobia.
Emmanuel NP; Brawman-Mintzer O; Morton WA; Book SW; Johnson MR; Lorberbaum JP; Ballenger JC; Lydiard RB
Depress Anxiety; 2000; 12(2):111-3. PubMed ID: 11091936
[TBL] [Abstract][Full Text] [Related]
11. Bupropion sustained release: a therapeutic overview.
Davidson JR; Connor KM
J Clin Psychiatry; 1998; 59 Suppl 4():25-31. PubMed ID: 9554318
[TBL] [Abstract][Full Text] [Related]
12. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.
Reimherr FW; Cunningham LA; Batey SR; Johnston JA; Ascher JA
Clin Ther; 1998; 20(3):505-16. PubMed ID: 9663366
[TBL] [Abstract][Full Text] [Related]
13. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners.
Moss EL; Simpson JS; Pelletier G; Forsyth P
Psychooncology; 2006 Mar; 15(3):259-67. PubMed ID: 16041840
[TBL] [Abstract][Full Text] [Related]
14. Improving antidepressant adherence.
Nemeroff CB
J Clin Psychiatry; 2003; 64 Suppl 18():25-30. PubMed ID: 14700452
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling.
McCarthy DE; Piasecki TM; Lawrence DL; Jorenby DE; Shiffman S; Fiore MC; Baker TB
Nicotine Tob Res; 2008 Apr; 10(4):717-29. PubMed ID: 18418793
[TBL] [Abstract][Full Text] [Related]
16. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
[TBL] [Abstract][Full Text] [Related]
17. Bupropion XL for the sustained treatment of trichotillomania.
Klipstein KG; Berman L
J Clin Psychopharmacol; 2012 Apr; 32(2):298-9. PubMed ID: 22388165
[No Abstract] [Full Text] [Related]
18. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
[TBL] [Abstract][Full Text] [Related]
19. Steady-state clinical pharmacokinetics of bupropion extended-release in youths.
Daviss WB; Perel JM; Birmaher B; Rudolph GR; Melhem I; Axelson DA; Brent DA
J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1503-9. PubMed ID: 17135996
[TBL] [Abstract][Full Text] [Related]
20. Varenicline and bupropion sustained-release combination therapy for smoking cessation.
Ebbert JO; Croghan IT; Sood A; Schroeder DR; Hays JT; Hurt RD
Nicotine Tob Res; 2009 Mar; 11(3):234-9. PubMed ID: 19246427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
